Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rademikibart (Primary)
Indications Nasal polyps; Rhinosinusitis
Focus Therapeutic Use
Sponsors Connect Biopharma Australia

Most Recent Events

29 Jun 2022 Status changed from active, no longer recruiting to discontinued. Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.
11 May 2022 Status changed from recruiting to active, no longer recruiting.
08 Sep 2021 According to a Connect Biopharma Australia media release, Dr. Rodney J. Schlosser is an investigator in the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com